Wyeth Premarin Shortage Is Opportunity To Shift Patients To Cenestin – Barr
Executive Summary
Barr views current shortages of Wyeth-Ayerst's estrogen replacement therapy Premarin as an opportunity to encourage patient switches to its competing conjugated estrogen product Cenestin, Barr Senior VP-Sales & Marketing Timothy Catlett told analysts Dec. 6
You may also be interested in...
Wyeth Premarin Biannual Price Increases To Boost "Cheap" 60[cents] Daily Cost
Wyeth-Ayerst will adopt a biannual price increase strategy for the hormone replacement therapy Premarin, the company told analysts during its second quarter earnings call July 24.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials